InflaRx(NASDAQ) IFRX

Market Cap$257.76M

Since IPO (2017)-88%

5 Year-30%

1 Year+103%

1 Month-22%

$1.75

-0.29%

-0.01Today

InflaRx last closing stock price
Metric	Price	Date
Last close	USD 1.75	2026-08-03

InflaRx stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+2.94%	USD 1.70	2026-07-27
1 month	-21.88%	USD 2.24	2026-07-02
3 month	-11.17%	USD 1.97	2026-05-05
Year to date	+73.27%	USD 1.01	2025-12-31
1 year	+103.49%	USD 0.86	2025-08-01
3 year	-53.15%	USD 3.74	2023-08-04
5 year	-30%	USD 2.50	2021-08-04
Since inception	-88.33%	USD 14.99	2017-11-08

InflaRx Financials at a Glance

Market Cap

$257.76M

Revenue (TTM)

€29.33K

Net Income (TTM)

-€42.91M

EPS (TTM)

$0.00

P/E Ratio

-1.67

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Price

$1.75

Volume

404,336.294

Open

$1.79

Price

$1.75

Volume

404,336.294

Open

$1.79

Previous Close

$1.75

Daily Range

$1.72 - $1.88

52-Week Range

$0.74 - $2.95

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Price

$1.75

Volume

404,336.294

Open

$1.79

Previous Close

$1.75

Daily Range

$1.72 - $1.88

52-Week Range

$0.74 - $2.95

Estimated Earnings Date

Aug 6, 2026

IFRX News

Why InflaRx Stock Skyrocketed This Week

Keith NoonanApr 7, 2023

nurse and doctors in masks discussing chart

Why Shares of InflaRx Are Soaring Wednesday

James HalleyApr 5, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InflaRx

InflaRx N.V. is a biopharmaceutical company focused on developing therapies that target the complement system, an essential part of the immune system. The company aims to treat inflammatory diseases with unmet medical needs by developing innovative monoclonal antibodies.

Products and Services

Treatments targeting the complement component C5a to manage inflammation.

Monoclonal antibodies designed to precisely inhibit specific parts of the immune system.

Robust research and development pipeline focused on inflammatory diseases.

What Makes InflaRx N.V. Special

InflaRx stands out due to its focus on monoclonal antibodies that specifically target C5a, an inflammatory component, offering potentially safer and more effective treatments compared to broad-spectrum anti-inflammatory drugs.

Five Things You Need to Know

InflaRx specializes in targeting the complement system, a key part of the immune response.

The company's leading approach involves inhibiting C5a, aiming for improved treatment outcomes in inflammatory diseases.

InflaRx is led by industry veterans with extensive experience and a strategic vision for growth.

The growth strategy includes advancing drug candidates through clinical trials and expanding its research pipeline.

InflaRx seeks to address therapeutic gaps across multiple indications for long-term growth and stakeholder value.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Niels Christoph Riedemann, MD, PhD

Website

www.inflarx.de

Headquarters

Jena, TH 07745, DE

IFRX Financials

Key Financial Metrics (TTM)

Gross Margin

-24646.27%

Operating Margin

-144444.96%

Net Income Margin

-146303.92%

Return on Equity

-94.90%

Return on Capital

-113.72%

Return on Assets

-87.68%

Earnings Yield

-59.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$257.76M

Shares Outstanding

147.29M

Volume

404.34K

Avg. Volume

1.80M

Financials (TTM)

Gross Profit

-€7.23M

Operating Income

-€42.37M

EBITDA

-€42.36M

Operating Cash Flow

-€28.81M

Capital Expenditure

-€114.87K

Free Cash Flow

-€28.93M

Cash & ST Invst.

€39.84M

Total Debt

€823.89K

InflaRx Performance Analysis

InflaRx annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 0	N/A
2023	2023-12-31	EUR 68,207	N/A
2024	2024-12-31	EUR 179,332	162.9%
2025	2025-12-31	EUR 33,102	-81.5%

InflaRx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	-39.6%
Q4	2025-12-31	-242.4%
Q1	2026-03-31	100.0%

InflaRx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -0.70	-45.9%
2023	2023-12-31	EUR -0.84	19.8%
2024	2024-12-31	EUR -0.85	0.7%
2025	2025-12-31	EUR -0.77	-9.5%

InflaRx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-61.5%
Q3	2025-09-30	14.3%
Q4	2025-12-31	22.2%
Q1	2026-03-31	43.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

€0.00

N/A

Gross Profit

€0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$257.76M

N/A

Market Cap/Employee

$3.97M

N/A

Employees

N/A

Net Income

-€5.59M

+32.7%

EBITDA

-€5.49M

+33.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

€39.84M

-39.5%

Total Debt

€823.89K

+17.3%

Accounts Receivable

€1.65M

-2.4%

Inventory

€0.00

-100.0%

Long Term Debt

€572.33K

+93.7%

Short Term Debt

€251.55K

-38.2%

Return on Assets

-87.68%

N/A

Return on Invested Capital

-1.13%

N/A

Free Cash Flow

-€7.52M

+46.4%

Operating Cash Flow

-€7.51M

+46.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

STROSutro Biopharma, Inc.

STROSutro Biopharma, Inc.$25.80+2.80%

ARTVArtiva Biotherapeutics, Inc.

ARTVArtiva Biotherapeutics, Inc.$11.05+2.65%

STTKShattuck Labs, Inc.

STTKShattuck Labs, Inc.$7.51+2.98%

CNTBConnect Biopharma Holdings Limited

CNTBConnect Biopharma Holdings Limited$2.13+8.12%

KLRSKalaris Therapeutics Inc

KLRSKalaris Therapeutics Inc$4.28+5.68%

IMAImageneBio Inc

IMAImageneBio Inc$5.75+1.95%

CNTXContext Therapeutics Inc.

CNTXContext Therapeutics Inc.$0.63+3.84%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PLTRPalantir Technologies

PLTRPalantir Technologies$159.60+0.27%

NOKNokia

NOKNokia$9.96+0.06%

AMIXAutonomix Medical

AMIXAutonomix Medical$9.24+1.53%

INTCIntel

INTCIntel$99.92+0.10%

SNAPSnap

SNAPSnap$5.78+0.15%

NVDANvidia

NVDANvidia$210.40+0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$38.14-0.08%

Questions About IFRX

What is the current price of InflaRx?

InflaRx is trading at $1.75 per share.

What is the 52-week range for InflaRx?

Over the past 52 weeks, InflaRx has traded between $0.74 and $2.95.

How much debt does InflaRx have?

As of the most recent reporting period, InflaRx reported total debt of €948.29K.

How much cash does InflaRx have on hand?

InflaRx reported €17.28M in cash and cash equivalents in its most recent financial results.

What is InflaRx’s dividend yield?

InflaRx does not currently have a dividend yield.

InflaRx(NASDAQ) IFRX

InflaRx Financials at a Glance

IFRX News

Why InflaRx Stock Skyrocketed This Week

Why Shares of InflaRx Are Soaring Wednesday

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About InflaRx

Products and Services

What Makes InflaRx N.V. Special

Five Things You Need to Know

IFRX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

InflaRx Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IFRX

What is the current price of InflaRx?

What is the 52-week range for InflaRx?

How much debt does InflaRx have?

How much cash does InflaRx have on hand?

What is InflaRx’s dividend yield?

Premium Investing Services